Skip to main content
15 August 2026
25 September 2025

Aquavit Pharmaceuticals Expands AI Capabilities with Acquisition of Axon Technologies

Aquavit Pharmaceuticals AG announced the successful acquisition and integration of Axon Technologies AG, formerly known as Genève Technologies, marking a strategic leap forward in artificial intelligence (AI) and advanced life-science innovation. “By bringing Axon Technologies into the Aquavit family, we fuse world-c…

24 September 2025

LabConnect Partners with The Bracken Group to Boost Radiopharma Support

LabConnect, a leading provider of global central laboratory and support services for clinical trials, announces a strategic collaboration with The Bracken Group to enhance its radiopharmaceutical support capabilities. As demand for radiopharmaceutical expertise continues to surge, with industry growth estimated betwe…

24 September 2025

GCCL and Frontage Labs Sign Strategic MOU to Boost Global Clinical Trials

GCCL (Global Clinical Central Lab), a South Korea-based leading provider of clinical trial sample analysis, and Frontage Laboratories, Inc., a USA based full-service contract research organization (CRO), announced that they had signed a strategic Memorandum of Understanding (MOU) pursuant to which they intend to explo…

23 September 2025

AstraZeneca and SOPHiA GENETICS Partner to Advance Precision Oncology with AI & NGS

SOPHiA GENETICS, an AI technology company transforming precision medicine, announced an expansion of its collaboration with AstraZeneca from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate cancer by developing an optimized next generation sequenc…

22 September 2025

Roche to Acquire 89bio, Boosting Liver & Cardiometabolic Pipeline

Roche announced that it has entered into a definitive merger agreement to acquire 89bio, Inc., a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases. This acquisition underscores Roche’s dedication to advan…

22 September 2025

Biogen to Acquire Alcyone Therapeutics, Expands Neurology Pipeline

Biogen Inc. announced the company has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therapeutics. As part of an existing partnership with Alcyone Therapeutics, the companies are advancing ThecaFlex DRx™, an implantable subcutaneous port and catheter device being investigated for the intrat…

19 September 2025

FUJIFILM Strengthens Global Collaboration with argenx in Biologics Manufacturing

FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, announced a significant expansion of its global partnership with argenx SE, a global immunology company. As part of the expanded agreement, FUJIFILM Biotechnologies will initia…

19 September 2025

Alnylam Joins Illumina & NashBio’s Alliance for Genomic Discovery

Illumina, Inc., and Nashville Biosciences, LLC, announced Alnylam Pharmaceuticals, Inc. as a member of the Alliance for Genomic Discovery (AGD). Alnylam, a pioneer in RNA interference (RNAi) therapeutics, will utilize the AGD clinical genomic database to derive real-world insights and accelerate drug target discovery.…

18 September 2025

Mabwell and Aditum Bio Launch Kalexo Bio for Novel siRNA Therapy

Mabwell (Shanghai) Bioscience Co., Ltd. and Aditum Bio today announced the launch of Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement to develop 2MW7141, a novel dual-target siRNA candidate for lipid management in patients with dyslipidemia and for the prevention of high-risk …

Page 27 of 36